There are already Chinese products, and the quality can also meet the standards of imported products, but domestic drugs are not selling imported or joint venture products. Such examples seem to be commonplace. For example, fat milk, 10 years ago, China had domestically produced domestic fat emulsions, and the price was much cheaper than that of the joint venture company, but the fat milk products produced by the joint ventures still occupied the same products in China. 95% of the market's share, and domestic fat milk has not yet opened the market; for example, recombinant human insulin, as early as a dozen years ago, Dr. Gan Zhongru’s recombined human insulin, which was founded by Dr. Gan Zhongru, was put into operation in Beijing and Tonghua, respectively. The annual output had reached 2 tons four or five years ago, but up until now, human insulin products produced by Tonghua Dongbao or Beijing Ganli Pharmaceutical have rarely been seen in domestic hospitals or pharmacies.
Where are the human insulin products with independent intellectual property rights produced by pharmaceutical companies in China? Why are there only recombinant human insulin products produced by Novo Nordisk, Eli Lilly or Sanofi-Atevan on the market?
Due to its strong economic strength and marketing network throughout the country, foreign companies have succeeded in keeping domestic human insulin out of the market, together with the interest chain formed by hospitals and pharmaceutical distribution companies. Domestically produced recombinant human insulin can only take the old road that most domestic pharmaceutical companies are still on the way to export insulin raw material drugs to foreign countries, and then processed by foreign manufacturers into their domestic sales.
It is understood that Tonghua Dongbao has developed and marketed its own new brand insulin injection pen Gan Shulin as early as several years ago. Its retail price is 59.9 yuan, and its new Dongbao automatic insulin injection pen is also Only 196 yuan. In contrast, similar products produced by Novo Nordisk each cost about 288-360 yuan. However, it is surprising that in the hospitals or pharmacies in East China, the low-cost insulin pens of Tonghua Dongbao are almost out of sight.
The selling price of insulin pens for foreign assets sold on the market in China is much higher than other countries in Asia, and even more expensive than those in Europe and the United States. According to the survey, the retail price of insulin pens (each 3.0 ml or 300 units) in the Chinese market is generally 288-300 yuan, while the retail price of insulin pens in other countries with the same specifications is in the US market. The cost is 15-17 dollars (there are more than 5 purchases at a time and there is a discount); each EU unit sells for around 12 euros. In other words, in the European and American markets, the retail price of each 3.0-millimeter insulin pen was converted into RMB 106-120, which is much lower than the selling price in the Chinese market. In Asia, India's selling price is converted into RMB80-90 per unit; Pakistan's selling price is similar to India's; 3.0ml insulin injection pens are used in Southeast Asian countries such as Malaysia, Singapore and Thailand where the economy is relatively developed. The selling price is only 120-150 RMB; Egypt's price is converted into RMB 85-120. It seems that China has become one of the most expensive countries in the world for insulin injection pens. And China’s per capita national income is reported to have ranked more than 100 in the world.
Since the domestic market is basically controlled by expensive foreign-funded products, inexpensive domestic insulin pens are difficult to open up, which in turn leads to a low penetration rate of insulin pens in diabetic patients in China, which is less than 3%; In western European countries, the penetration rate of insulin pens for diabetics is 50%; in the United States, 30% (American diabetics prefer to use insulin pump delivery devices); even in India where per capita national income is not high internationally, The penetration rate of its use is also 8% to 10%; in Malaysia, Singapore and Thailand and other Southeast Asian countries, its use penetration rate is also more than 15%, much higher than our country.
Although the popularity of insulin pens is low, foreign investors are not worried about the sales of their products in the Chinese market. There are currently 50 million diabetic patients in China. There are always some patients who must purchase at their own expense due to the condition of the disease. According to reports, Novo Nordisk, Eli Lilly, and Sanofi-Atewan have plans to expand the production of insulin pens in China, and China's domestic insulin pen manufacturers have struggled so far, and most of their insulin raw material production capacity has been released. Some insulin bulk drugs can only be exported to overseas markets.
Insulin injection pens have long been monopolized by foreign investors for more than 20 years. They directly harm the interests of the majority of diabetic patients (most of them belong to the middle and low-income groups). They are eager to purchase low-priced products, hoping that relevant departments will take in India, Pakistan and Egypt. Such as developing countries, as soon as possible to establish the ceiling price of such products, so that cheap domestic pen insulin can benefit low-income patients.
Shenzhen Ousida Technology Co., Ltd
